Cargando…
Anthracycline Chemotherapy and Cardiotoxicity
Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer. Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer survivor to increased cardiovascular morbidity and mortality. The basic mechanisms of cardiotoxicity may involve direct p...
Autores principales: | McGowan, John V, Chung, Robin, Maulik, Angshuman, Piotrowska, Izabela, Walker, J Malcolm, Yellon, Derek M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346598/ https://www.ncbi.nlm.nih.gov/pubmed/28185035 http://dx.doi.org/10.1007/s10557-016-6711-0 |
Ejemplares similares
-
Ischaemic Preconditioning Protects Cardiomyocytes from Anthracycline-Induced Toxicity via the PI3K Pathway
por: Maulik, Angshuman, et al.
Publicado: (2018) -
Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC‐ONC Study—A Single‐Center, Blinded, Randomized Controlled Trial
por: Chung, Robin, et al.
Publicado: (2016) -
Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
por: Briasoulis, Alexandros, et al.
Publicado: (2022) -
Anthracyclines and Biomarkers of Myocardial Injury: The Effect of Remote Ischemic Conditioning
por: Mallouppas, Michael, et al.
Publicado: (2023) -
Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
por: Broeyer, F. J. F., et al.
Publicado: (2008)